India, May 21 -- Biocon Biologics Ltd (BBL), a global integrated biosimilars company and a subsidiary of Biocon Ltd, announced the launch of Ustekinumab BS Subcutaneous Injection [YD] in Japan through its commercial partner Yoshindo Inc. This biosimilar is equivalent to the reference drug Stelara® (ustekinumab) and has been developed and manufactured by Biocon Biologics.
The biosimilar ustekinumab is approved for treating psoriasis vulgaris and psoriatic arthritis (PsA). Yoshindo Inc. is responsible for marketing and commercializing the product in Japan.
This launch follows a settlement and licensing agreement signed in April 2024 between Biocon Biologics and Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (colle...